|
Series | Year | No. of patients | Implant/allograft and site of the tumor | Survival of the allograft at last follow-up | Complications/revision | Infection | Recurrence | MSTS score |
|
(1) Manfrini et al. [12] | 1999 | 10 | Vascularized fibula graft and massive allograft | | Valgus deformity limb-length discrepancy 2–3.5 cm | None reported | None reported, but 4 were lost for follow-up | Satisfactory |
(2) Aponte-Tinao et al. [7] | 2015 | 35 | Epiphyseal preservation and allograft tibia and femur | Overall survival rate of the patients was 86% at 5 years | 14 (40%) patients Fracture and nonunion. Removal in 10 patients | 2 (6%) | 3 | The mean functional score was 26 points at final follow-up |
(3) Agarwal et al. [3] | 2010 | 19 | Bone allograft, autograft, or vascularized fibula | 16/25 at a median follow-up of 34 months. There were four deaths | 4 (22%) fracture and nonunion | 2 (10%) | 4 | The musculoskeletal tumor society score ranged from 27 to 30 |
(4) Abdelaal et al. [9] | 2015 | 18 | Epiphyseal sparing and reconstruction | Five- and ten-year rates of survival were 94.4% | Fracture of the graft and nonunion in 2 patients (11%) | 2 (11%) | 1 | MSTS score was excellent in 17 patients (94.4%) and poor in one (5.5%) |
(5) Li et al. [11] | 2017 | 41 | Vascularized fibula and bone allograft | All at follow-up of 3–11 years Mean 4.4 years | Revision in 10 patients (24%) osteonecrosis in remaining epiphysis in 13 patients. (31%) | | 3 | MSTS score 22–30 Median = 28 |
(6) Muratori et al. [13] | 2018 | 64 | Resections around ankle, knee, and hip | Mean follow-up was 117 months (12–305) | Fracture 26%. Nonunion 14% | 3 patients (4.7%) | Not reported | 27 (18–30) |
|